swiftscale’s Post

CellVoyant Secures £7.6M Funding for Groundbreaking AI-Enhanced Cell Imaging-John Pinching CellVoyant, a University of Bristol AI biotechnology spin-out, has secured £7.6 million in a funding round led by Octopus Ventures. The investment, with participation from Horizons Ventures, Air Street Capital, and Verve Group Ventures, will support the commercialization of CellVoyant's AI and live cell imaging platforms. The technology combines advanced AI with real-time live cell imaging to extract spatial and temporal information from millions of cells. This innovation aids scientists in understanding cell composition and predicting their evolution, particularly in the development of novel cell therapies. The funding will also be utilized to expand infrastructure, increase headcount, and support further research and development. Rafael E. Carazo Salas,Rickard Sjögren,Tünde Berecz, PhD,Evelyn Welch #CellVoyant #AI #Biotechnology #CellImaging #Funding #News #TrendingNews

🌟 Exciting News 🌟 GC Therapeutics, a groundbreaking biotech startup, has officially launched with a remarkable $75 million in financing. The startup, founded on research from George Church’s lab at Harvard Medical School and the Wyss Institute at Harvard University, is paving the way for transforming stem cells into a wide range of human cells. The innovative idea behind GC Therapeutics emerged from the frustrations of founders Alex Ng, Ph.D. and Parastoo Khoshakhlagh, Ph.D. with the slow and complex methods used in stem cell therapies. Their dedication led to the discovery of a systematic approach using transcription factors to rapidly convert stem cells into vital cells like those found in blood vessels, the brain, and connective tissues. Congratulations to the entire team on this remarkable achievement! 🚀💡 #Biotech #Innovation #StemCells #RegenerativeMedicine #StartupLife #stemcell #75m #funding #financing #biotechnology #advancedtherapies #regenerativemedicine #lifescience #lifesciences #celltherapies #cellandgenetherapies #startup #transcriptionfactors

“Somite Therapeutics a venture-backed company aiming to become the OpenAI of stem cell biology, announces that it has raised $5.3M in pre-seed funding. The round was led by Israel's preeminent Venture fund TechAviv, and joined by renowned Austin-based VCs Next Coast Ventures, Trust Ventures and Texas Venture Partners as well as NY-based Lerer Hippeau and others. The funds will be used to continue development of Somite's proprietary AlphaStem AI platform, building Somite labs and bringing the first therapeutic asset to phase 1 clinical trials.” #biotech #techbio #scienceandtechnology #ai #ml #stem #lifesciences #therapeutics https://lnkd.in/eUKyTajs

Finland’s StemSight gains access to CRISPR/Cas9 technology through collaboration with ERS Genomics for corneal blindness therapies Tampere-based StemSight - Vision Unlimited and US-based ERS Genomics have signed a non-exclusive agreement allowing StemSight access to ERS Genomics’ CRISPR/Cas9 patent portfolio. StemSight, a biotech company working on stem cell-based therapies for corneal blindness, considers this partnership a significant step forward. By using CRISPR/Cas9 technology, StemSight aims to address challenges in existing cell therapies and move closer to developing transformative treatments for patients with incurable blindness. ERS Genomics, a CRISPR licensing company, is pleased with the collaboration and acknowledges the growing importance of Finland in the global biotech and life science sector. The financial details of the agreement have not been disclosed. https://lnkd.in/dshEjPxU #community #partnerships #nordicmade #finland #CRISPR #biotech #healthtech #deeptech #medtech #trending

Will AI revolutionize cell therapy? This new startup, Somite.ai, certainly believes so. Their team is dedicated to making this dream a reality. With the power of openAI and stem cells, the possibilities are endless. We can't wait to see what they accomplish. #celltherapy #openAI #Stemcells #startup #technology #Somite.ai

Just back from the extraordinary LongBio Conference at Vitalia, where as a speaker representing Vincere Biosciences, I had the privilege to be part of a groundbreaking event that brought together around 200 of the world's most forward-thinking longevity biotech founders, investors, futurists, and bio-accelerationists. The Vitalia Vision: The two-month 'pop-up city' concept of Vitalia blends co-living, conferences, and a global community dedicated to radical life extension. The immersive experience of living and collaborating in such an innovative space is game-changing opportunity for the longevity biotech field. Insightful Discussions and Talks Including: Promising New Interventions: Dr. Jeanne Loring's talk on stem cell therapeutics for Parkinson's disease was a standout with a method of generating new dopamine neurons from the patients own tissue that is nearing first human trials. Reason's data on Repair Biotechnologies treatment for atherosclerosis also looks like a compelling way to degrade excess cholesterol. Off-Shore Clinical Trials: The concept of off-shore clinical trials, as presented by Dr. Glenn Terry, opens up new frontiers in medical research. His work with the The GARM Clinic in Roatan illustrates the benefits of leveraging unique regulatory environments to accelerate medical innovation. While the conversations strongly recognized the need to prioritize safety and rigor there is hope that jurisdictions like Próspera /Vitalia.city might shave time to first-in-human trials for areas of high unmet need (including the work of Aspen and Vincere around Parkinson's disease). Decentralized Finance in Biotech: Laurence Ion's insights on how decentralized finance (DeFi) is revolutionizing the way investors fund new companies were eye-opening. The shift away from traditional intermediaries is a significant leap towards democratizing investment in cutting-edge biotech ventures with early financing through projects like VitaDAO and tokenized IP that might be fractionally sold. My take might ruffle a few feathers - DeFi is great, but it doesn't necessarily need to be on the blockchain! We have a fantastic cohort of distributed stakeholders using TradFi instruments like SAFEs and stock. Networking and Collaborations: The sidelines of the conference were as enriching as the main events. Conversations with fellow speakers like Aubrey de Grey, Martin Ducker, Matthew Scholz, and José Luis Cordeiro were illuminating. The opportunity to interact and brainstorm with such a diverse and talented group was invaluable. A big thank you to the organizers (h/t to Sebastian A. Brunemeier), fellow speakers, and attendees who made this such a memorable experience. The journey to a longer, healthier future is well underway, and I'm thrilled to be a part of it. For more details on the conference and upcoming events at Vitalia, check out https://Vitalia.city #LongBioConference #Vitalia #LongevityBiotech #Innovation #HealthTech #FutureOfMedicine

🚨🧠 Celebrations are well in order for the team at INBRAIN Neuroelectronics as they announce an additional $50M in new #financing toward their graphene-based #braincomputerinterface therapeutics (BCI-Tx) platform. INBRAIN Neuroelectronics latest series B #funding round was led by, imec.xpand, with new #investors EIC Fund, Fond ICO Next Tech, CDTI-Innvierte and Avançsa. Legacy investors Asabys Partners, Aliath Bioventures, and Vsquared were also involved in the round as well. In addition to the Series B round, Merck KGaA also announced they were partnering with INBRAIN Neuroelectronics in support of their clinical development as well as future innovation to collaborate with Merck's therapeutic interests. "INBRAIN Neuroelectronics is pioneering a groundbreaking approach to BCI technology using grapheneThis unique graphene-based BCI platform has the potential to redefine how we treat neurological disorders by offering more precise, adaptable, and intelligent therapeutics. We look forward to supporting the INBRAIN team in accelerating their clinical trials and bringing this next-generation technology to patients.” - Frank Bulens, Partner at imec.xpand #neuroinnovation #medtechmoney #braincomputerinterface #neurodisease The Mullings Group

🚀 Exciting Advances in Biomedical Sciences! 🧬 I recently came across some fascinating innovations in the field of biomedical sciences that I wanted to share. One standout is the development of autonomous experimentation (AE) systems. These AI-driven platforms are revolutionizing research and development by running numerous experiments autonomously, significantly accelerating discoveries in areas like drug discovery and precision oncology. 🌟 For more details, check out this insightful article:https://lnkd.in/eNU3bRtn. #BiomedicalScience #MedicalResearch #Innovation #AI #Healthcare

Success stories are our favourites! Congratulations to Team BioThrust for securing a significant 7-digit investment from Frank Thelen and his VC Freigeist. 💰 At the heart of this achievement lies a pressing problem: Stem cell therapies hold immense promise in treating diseases like cancer, Alzheimer's, and Parkinson's. However, the current procedures are prohibitively expensive, limiting access to these life-changing treatments. The RWTH Aachen University spinoff has developed gassing solutions for bioreactors which prevent the formation of bubbles and circumvent foam, making their reactor and ideal environment to grow stem cells in. This breakthrough isn't just about innovation; it's about transforming lives. With their pioneering technology, BioThrust aims to democratize access to stem cell therapies, potentially revolutionizing medical research and treatment outcomes. What a remarkable achievement! 👏 #investment #startup #biotech #lifescience